Servier

Founded 70 years ago to serve health, Servier is a worldwide pharmaceutical group overseen by a non-profit Foundation, aiming to create a meaningful social impact for patients and a sustainable world. This distinctive governance model preserves the Group’s independence, allowing it to fully pursue its mission of advancing therapeutic progress to meet patient needs with a long-term perspective. Its staff are entirely dedicated to this shared mission, which inspires them daily. A global leader in cardiometabolism and venous diseases, Servier has made a significant move into oncology, now a key pillar of its strategic expansion. The Group allocates nearly 70% of its R&D budget to this area, seeking to become a focused and innovative player in treatments for rare cancers. Neurology is set to be a future growth area, with Servier concentrating on a select set of diseases where precise patient profiling enables targeted therapy via precision medicine. To ensure broad access to affordable, high-quality care, the Group also provides a range of generic drugs covering most conditions, relying on established brands in France, Eastern Europe, and Brazil. Across these fields, patient needs are considered at every step of the medicine’s lifecycle. Based in France, Servier benefits from dedicated teams and a strong international presence, with its medicines reaching nearly 140 countries. In 2023/2024, the Group posted sales of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, Servier employs more than 22,000 people worldwide. -- To report a suspected side effect of a Servier medication, go to servier.com.